LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes^[1]. LR-90 is also used in the research of diabetic animal model^[2]. IC50 & Target: AGE^[1] In Vitro: LR-90 (0, 25, 50, 100, and 200 μM) inhibits RAGE, MCP-1, COX-2, IP-10 and NOX2 mRNA expression in THP-1 cells in a dose-dependent manner, after pretreatment 1 h befor S100b stimulatation for 4 hours^[1].
LR-90 (0, 25, 50, 100, and 200 μM) dose-dependently and significantly blocks THP-1 cells adherence to endothelial cells after pretreatment 1 h befor S100b stimulatation for 24 hours^[1].
LR-90 (0, 25, 50, 100, and 200 μM, for 24 hours) shows no effect on the cell viability of THP-1 cells^[1]. In Vivo: LR-90 (50 mg/L, p.o. for 27 weeks) significantly reduces plasma lipids, modestly affects hyperglycaemia in ZDF rats^[2].
LR-90 (50 mg/L) decreases renal AGE, AGER and lipid peroxidation^[2].